MedPath

Investigating the effect of Butyrate on inflammatory genes and apoptosis in Ulcerative colitis

Phase 3
Recruiting
Conditions
lcerative Colitis Inflammation.
Ulcerative colitis
Registration Number
IRCT20221215056828N1
Lead Sponsor
Shiraz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Male or female 18 to 60 years old
Body mass index between 18.5 and 30
Estimating the severity of the disease based on the Mayo
The severity of the disease is mild to moderate
Patients with ulcerative colitis diagnosed by colonoscopy
Informed consent from the patient
Patients who are in the quiescent stage of the disease are included in the study, and patients who are in the acute stage of the disease are excluded.
The patient should refrain from any self treatment and use of herbal medicines.

Exclusion Criteria

Patients with other gastrointestinal diseases including intestinal obstruction, fistula, celiac disease, cancer and infectious diseases
Pregnancy and breastfeeding
Use of antibiotic drugs and other probiotic products and vitamin and mineral supplements for the previous 2 months.
History of hospitalization in the last 3 months
Type 2 diabetes patients
Acute stage of the disease
Change in the process of drug consumption during the study
Intensification of the disease during study
The place of implementation of the study is Faqihi Hospital and Motahari Clinic of Shiraz University of Medical Sciences

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in gene Sirt1 expression. Timepoint: At the beginning of the study and 3 months later (the end of the study). Method of measurement: Real time PCR.
Secondary Outcome Measures
NameTimeMethod
ife quality score. Timepoint: At the beginning of the study and 3 months later (the end of the study). Method of measurement: IBDQ9 questionnaire.
© Copyright 2025. All Rights Reserved by MedPath